Anti-CD20 monoclonal antibodies: historical and future perspectives

被引：182
作者：
Lim, Sean H. [1 ]
Beers, Stephen A. [1 ]
French, Ruth R. [1 ]
Johnson, Peter W. M. [1 ]
Glennie, Martin J. [1 ]
Cragg, Mark S. [1 ]
机构：
[1] Univ Southampton, Sch Med, Tenovus Lab, Gen Hosp,Canc Sci Div, Southampton SO16 6YD, Hants, England
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷 / 01期
关键词：
CD20; monoclonal antibodies; lymphoma; immunotherapy; NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; FC-GAMMA-RIIIA; CHEMOTHERAPY PLUS RITUXIMAB; FRESH-FROZEN PLASMA; FOLLICULAR LYMPHOMA; IN-VIVO; LOW-GRADE; PHASE-I/II;
D O I：
10.3324/haematol.2008.001628
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced.
引用
收藏
页码：135 / 143
页数：9
相关论文
共 114 条
[1]  
Alas S, 2001, CANCER RES, V61, P5137
[2]  
Alas S, 2001, CLIN CANCER RES, V7, P709
[3]   Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: Relationship to in vivo rituximab resistance [J].
Bannerji, R ;
Kitada, S ;
Flinn, IW ;
Pearson, M ;
Young, D ;
Reed, JC ;
Byrd, JC .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1466-1471
[4]   Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation [J].
Beers, Stephen A. ;
Chan, Claude H. T. ;
James, Sonya ;
French, Ruth R. ;
Attfield, Kathrine E. ;
Brennan, Claire M. ;
Ahuja, Anupama ;
Shlomchik, Mark J. ;
Cragg, Mark S. ;
Glennie, Martin J. .
BLOOD, 2008, 112 (10) :4170-4177
[5]   The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes [J].
Beum, PV ;
Kennedy, AD ;
Williams, ME ;
Lindorfer, MA ;
Taylor, RP .
JOURNAL OF IMMUNOLOGY, 2006, 176 (04) :2600-2609
[6]   Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab [J].
Bowles, Julie A. ;
Wang, Siao-Yi ;
Link, Brian K. ;
Allan, Barrett ;
Beuerlein, Gregory ;
Campbell, Mary-Ann ;
Marquis, David ;
Ondek, Brian ;
Wooldridge, James E. ;
Smith, Brian J. ;
Breitmeyer, James B. ;
Weiner, George J. .
BLOOD, 2006, 108 (08) :2648-2654
[7]   Pharmacokinetic and Pharmacodynamic Properties of TRU-015, a CD20-Directed Small Modular Immunopharmaceutical Protein Therapeutic, in Patients with Rheumatoid Arthritis: A Phase I, Open-Label, Dose-Escalation Clinical Study [J].
Burge, Daniel J. ;
Bookbinder, Stephen A. ;
Kivitz, Alan J. ;
Fleischmann, Roy M. ;
Shu, Cathye ;
Bannink, Jeannette .
CLINICAL THERAPEUTICS, 2008, 30 (10) :1806-1816
[8]   The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction [J].
Byrd, JC ;
Kitada, S ;
Flinn, IW ;
Aron, JL ;
Pearson, M ;
Lucas, N ;
Reed, JC .
BLOOD, 2002, 99 (03) :1038-1043
[9]   Neutrophil role in in vivo anti-lymphoma activity of rituximab:: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment [J].
Cartron, G. ;
Ohresser, M. ;
Salles, G. ;
Solal-Celigny, P. ;
Colombat, P. ;
Watier, H. .
ANNALS OF ONCOLOGY, 2008, 19 (08) :1485-1487
[10]   From the bench to the bedside: ways to improve rituximab efficacy [J].
Cartron, G ;
Watier, H ;
Golay, J ;
Solal-Celigny, P .
BLOOD, 2004, 104 (09) :2635-2642
12345678910